SCHEMBL4430846

SCHEMBL4430846

C=CCC(C#N)(CC=C)c1cccc(C)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
KIF11 P52732 5/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
KCNH2 Q12809 1/20 0.36
ACHE P22303 1/20 0.35
ALDH1A1 P00352 1/20 0.34
TSHR P16473 1/20 0.34
LMNA P02545 1/20 0.34
ATM Q13315 2/20 0.33
HTT P42858 1/20 0.33
SMN1; SMN2 Q16637 2/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
AR P10275 1/20 0.32
CASP1 P29466 1/20 0.32
HSD17B10 Q99714 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9080465 0.80 ALDH1A1 (0.38) KIF11CYP3A4ACHEALDH1A1TSHR
SCHEMBL7673680 0.80 KIF11 (0.40) KIF11CYP3A4ACHEALDH1A1SMN1; SMN2
SCHEMBL10624241 0.78 ALDH1A1 (0.48) CYP3A4CYP2D6ALDH1A1TSHRATM
SCHEMBL12681594 0.76 LMNA (0.42) TP53TDP1KIF11CYP3A4CYP2D6
SCHEMBL9080475 0.75 ACHE (0.37) KIF11CYP3A4ACHEALDH1A1TSHR
SCHEMBL12681590 0.75 TP53 (0.40) TP53TDP1KIF11CYP3A4CYP2D6
SCHEMBL2442297 0.74 ACHE (0.44) TP53TDP1KIF11CYP3A4CYP2D6
SCHEMBL9079258 0.73 KIF11 (0.37) KIF11CYP3A4ACHEALDH1A1SMN1; SMN2
SCHEMBL8031703 0.72 ALDH1A1 (0.43) CYP3A4CYP2D6ALDH1A1TSHRLMNA
SCHEMBL8031704 0.72 ALDH1A1 (0.43) CYP3A4CYP2D6ALDH1A1TSHRLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130012485-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2013-01-10 US disclosed
US-20130012485-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2013-01-10 US disclosed
US-20130012485-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2013-01-10 US disclosed
EP-2124913-A1 1-AMINOMETHYL- L- PHENYL- CYCLOHEXANE DERIVATIVES AS DDP-IV INHIBITORS Novartis AG (CH) 2009-12-02 EP disclosed
WO-2008077597-A1 1-AMINOMETHYL- L- PHENYL- CYCLOHEXANE DERIVATIVES AS DDP-IV INHIBITORS NOVARTIS AG (CH) 2008-07-03 WO disclosed
WO-2008077597-A1 1-AMINOMETHYL- L- PHENYL- CYCLOHEXANE DERIVATIVES AS DDP-IV INHIBITORS NOVARTIS AG (CH) 2008-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130012485-A1 ORGANIC COMPOUNDS DPP4, DPP3, DPP7 TP53 2421/4885TDP1 990/4885KIF11 4358/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.